Company Overview and News

 
New Pacific Reports Financial Results for the Year Ended June 30, 2018

2018-09-13 globenewswire
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- New Pacific Metals Corp. (“New Pacific” or the “Company”) today announced its audited consolidated financial results for the year ended June 30, 2018.
NUPMF NUXFF NUX

 
New Pacific Signs Memorandum of Understanding and Acquisition Option Agreement to Expand Land Package for Silver Sands Project

2018-07-25 globenewswire
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- New Pacific Metals Corp. (TSX-V:NUAG) (OTCQX:NUPMF) (“New Pacific” or the “Company”) is pleased to announce that the Company and its wholly-owned subsidiary, Empresa Minera Alcira S.A. (“Alcira”), signed a memorandum of understanding (the “MOU”) with Corporación Minera de Bolivia (“COMIBOL”), allowing Alcira to explore and develop 38 mineral concessions adjoining south and west to Alcira’s Silver Sands project in the Potosi Department of Bolivia.
SVM SVMLF NUPMF NUXFF PAAS NUX SVM

11
Top Silver Stocks For 2018: Midyear Update

2018-06-26 seekingalpha
My top picks for 2018 were Coeur Mining, New Pacific Metals, SilverCrest Metals, Arizona Mining and Silvercorp.
CDE SVCMF NUPMF NUXFF PAAS SOUHY NUX CDEUW SIL

 
New Pacific Reports Financial Results for the Three and Nine Months Ended March 31, 2018

2018-05-18 globenewswire
VANCOUVER, British Columbia, May 18, 2018 (GLOBE NEWSWIRE) -- New Pacific Metals Corp. (TSX-V:NUAG) (OTCQX:NUPMF) (“New Pacific” or the “Company”) today announced its unaudited condensed consolidated interim financial results for the three and nine months ended March 31, 2018.
NUPMF NUXFF NUX

 
Silvercorp Metals: Deep Value With Strong Fundamentals

2018-05-16 seekingalpha
Silvercorp Metals is deeply undervalued with no long-term debt and lots of cash. It is the cheapest among its peers.
SVM SVMLF NUPMF NUXFF NUX SVM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:NUX / New Pacific Metals Corp on message board site Silicon Investor.

RedHat Linux distributor -- IPO RedHat Linux distributor -- IPO RedHat Linux distributor -- IPO Linux OS.: Technical questions Linux OS.: Technical questions Linux OS.: Technical questions
LINUX LINUX LINUX VA Linux Systems Inc-(Nasdaq:LNUX) VA Linux Systems Inc-(Nasdaq:LNUX) VA Linux Systems Inc-(Nasdaq:LNUX)
BLUEPOINT LINUX (BLPT), the RED HAT of CHINA??.... BLUEPOINT LINUX (BLPT), the RED HAT of CHINA??.... BLUEPOINT LINUX (BLPT), the RED HAT of CHINA??.... Microsoft vs. Linux Microsoft vs. Linux Microsoft vs. Linux
Linuxcare, Inc. (LXCR) Linuxcare, Inc. (LXCR) Linuxcare, Inc. (LXCR) LINUX STOCKS: FIND THEM NOW, RETIRE EARLY LINUX STOCKS: FIND THEM NOW, RETIRE EARLY LINUX STOCKS: FIND THEM NOW, RETIRE EARLY
ATT - Linux ATT - Linux ATT - Linux LNUX: VA Linux Systems, Inc. LNUX: VA Linux Systems, Inc. LNUX: VA Linux Systems, Inc.